Expected and unexpected effects after systemic inhibition of Hippo transcriptional output in cancer

Isabel Baroja1,2, Nikolaos C Kyriakidis3, Georg Halder4

  • 1Cancer Research Group, Faculty of Engineering and Applied Sciences, Universidad de Las Américas, Quito, Ecuador.

Nature Communications
|March 28, 2024
PubMed

Insights

Hyperactivation of YAP/TAZ (Yes-associated protein/T-and-மானது-like protein) is common in cancer. Inhibiting these Hippo pathway effectors shows promise but requires careful consideration due to their dual roles in tumor suppression and promotion.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cell Signaling

Background:

  • Aberrant activation of YAP/TAZ, key downstream effectors of the Hippo pathway, is frequently observed in various human cancers.
  • YAP/TAZ proteins are crucial for cancer cell survival, leading to the development of targeted pharmacological inhibitors.

Purpose of the Study:

  • To review the multifaceted role of the Hippo pathway within distinct tumor cell populations.
  • To discuss the implications of inhibiting Hippo pathway output on tumor progression and growth.
  • To examine the current landscape and advancements in YAP/TAZ inhibitor development.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of the dual role of YAP/TAZ in cancer (tumor-promoting vs. tumor-suppressive).
  • Evaluation of current pharmacological YAP/TAZ inhibitors and their mechanisms.

Main Results:

  • YAP/TAZ activity is essential for cancer cell survival in preclinical models.
  • Systemic inhibition of YAP/TAZ can lead to unpredictable patient outcomes due to context-dependent functions.
  • YAP/TAZ exhibit both tumor-promoting and tumor-suppressive roles depending on the cellular context.

Conclusions:

  • The Hippo pathway and its effectors YAP/TAZ play complex roles in cancer, necessitating a nuanced approach to therapeutic inhibition.
  • Understanding the cell-type-specific functions of YAP/TAZ is critical for developing effective and safe cancer therapies.
  • Further research into YAP/TAZ inhibitors is needed to optimize their clinical application and mitigate potential adverse effects.

Related Concept Videos

Hedgehog Signaling Pathway02:33

Hedgehog Signaling Pathway

The Hedgehog gene (Hh) was first discovered due to its control of the growth of disorganized, hair-like bristles phenotype in Drosophila, much like hedgehog spines. Hh plays a crucial role in the development of organs and the maintenance of homeostasis in both invertebrates and vertebrates. However, while Drosophila has only one Hh protein, mammals have multiple functional Hedgehog proteins - Sonic (Shh), Desert (Dhh), and Indian Hedgehog (Ihh). All of these homologous proteins have adapted to...
7.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
Epigenetic Regulation01:37

Epigenetic Regulation

Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
3.0K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.7K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
Loss of Tumor Suppressor Gene Functions01:12

Loss of Tumor Suppressor Gene Functions

Tumor suppressor genes are normal genes that can slow down cell division, repair DNA mistakes, or program the cells for apoptosis in case of irreparable damage. Hence, they play an essential role in preventing the proliferation of damaged cells.
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
4.8K